3Unger J. Fredrickson. L. A. primer on imensive diabetes management and insulin pump therapy Primary Care Rop 1997; 3( 1 ): 9 -18.
4Sanfield JA, Hegstad M. Hanna Rs Protocol for outpatient screening and initiating of continuous subcutaneous insulin infusion therapy impact on cost and quality. Diabetes Educa 2002;28(4): 599- 607.
5Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycemia, better metabolic control, and improve quality of life in Type ldiabetes Mellitus with continuous subcutaneous insulin infusion(CSⅡ)therapy;an observational study of 100 consecutive patients followed for amean of 2 years. Diabetes Med 2002; 19 (9): 746 - 751.
6E. Torlone,C. Fanelli,A. M. Rambotti,G. Kassi,F. Modarelli,A. Vincenzo,L. Epifano,M. Ciofetta,S. Pampanelli,P. Brunetti,G. B. Bolli. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM[J] 1994,Diabetologia(7):713～720
6WHO.Dept of non-communicable disease surveillance [R] Geneva, 1999.
7Matsuda K,Hotta T,Takifuji K,et al. Long-term comor- bidity of diabetes mellitus is a risk factor for perineal wound complications after an abdominoperineal resection[J]. Langenbeck Arch Surg, 2009,394 (1) : 65-70.
8Ata A, Lee J, Bestle SL,et al. Postoperative hyperglycemia and surgical site infection in general surgery patients [J]. Arch Surg, 2010,145 (9) :858-864.
9Dhatariya K,Levy N,Kilvert A,et al. NHS Diabetes guide-line for the perioperative management of the adult patient with diabetes [J]. Diabetes Medicine,2012,29(4) : 420-433.
10Zaccardi F,Pitocco D,Ghirlanda G,et al. Glycemic risk factors of diabetic vascular complications :The role of glycemic variability [J]. Diabetes Metab Res Rev,2009, 25 : 199-207.
